Literature DB >> 26690342

Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence.

Margaret J Wortman1, Patric S Lundberg1, Ayuna V Dagdanova1, Pranav Venkataraman1, Dianne C Daniel1, Edward M Johnson1.   

Abstract

We document a unique DNA recombination between polyomavirus JC (JC virus [JCV]) and Epstein-Barr virus (EBV) at sequences of JCV found infecting the brain. Archetype JCV is present in bone marrow and uroepithelial cells of most adults. During immunosuppression, JCV can infect the brain, causing a demyelinating disease, progressive multifocal leukoencephalopathy. Rearrangements in the archetype noncoding control region are necessary for neurovirulence. Two NCCR deletions and a duplication occur at sequences of homology with EBV, present latently in B cells, which may be coinfected with both viruses. Recombination between JCV and EBV occurs in B lymphoblasts at a sequence essential for JCV neurovirulence and in cerebrospinal fluid of immunosuppressed patients with multiple sclerosis, those susceptible to progressive multifocal leukoencephalopathy. Interviral recombination is a model for conferring advantages on JCV in the brain. It can alter a critical noncoding control region sequence and potentially facilitate use of EBV DNA abilities to transfer among different cell types.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  AIDS; DNA replication; PML; interviral recombination; multiple sclerosis; progressive multifocal leukoencephalopathy

Mesh:

Year:  2015        PMID: 26690342      PMCID: PMC4813741          DOI: 10.1093/infdis/jiv755

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 2.  EBNA1 and host factors in Epstein-Barr virus latent DNA replication.

Authors:  Lori Frappier
Journal:  Curr Opin Virol       Date:  2012-09-30       Impact factor: 7.090

3.  Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Michael W Ferenczy; Elizabeth L Daley; Peter N Jensen; Caroline F Ryschkewitsch; Eugene O Major
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

4.  Break-induced replication repair of damaged forks induces genomic duplications in human cells.

Authors:  Lorenzo Costantino; Sotirios K Sotiriou; Juha K Rantala; Simon Magin; Emil Mladenov; Thomas Helleday; James E Haber; George Iliakis; Olli P Kallioniemi; Thanos D Halazonetis
Journal:  Science       Date:  2013-12-05       Impact factor: 47.728

5.  Roles of cell signaling pathways in cell-to-cell contact-mediated Epstein-Barr virus transmission.

Authors:  Asuka Nanbo; Haruna Terada; Kunihiro Kachi; Kenzo Takada; Tadashi Matsuda
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

6.  JC virus antibody status underestimates infection rates.

Authors:  Joseph R Berger; Sidney A Houff; Julie Gurwell; Nubia Vega; Craig S Miller; Robert J Danaher
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

7.  JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.

Authors:  Shruti P Agnihotri; Xin Dang; Jonathan L Carter; Terry D Fife; Evelyn Bord; Stephanie Batson; Igor J Koralnik
Journal:  Neurology       Date:  2014-07-18       Impact factor: 9.910

8.  JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.

Authors:  Elliot M Frohman; Maria Chiara Monaco; Gina Remington; Caroline Ryschkewitsch; Peter N Jensen; Kory Johnson; Molly Perkins; Julia Liebner; Benjamin Greenberg; Nancy Monson; Teresa C Frohman; Daniel Douek; Eugene O Major
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

9.  Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.

Authors:  Carl E Reid; Huo Li; Gargi Sur; Paul Carmillo; Steven Bushnell; Rich Tizard; Michele McAuliffe; Christopher Tonkin; Kenneth Simon; Susan Goelz; Paola Cinque; Leonid Gorelik; John P Carulli
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

Review 10.  Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy.

Authors:  Edward M Johnson; Margaret J Wortman; Ayuna V Dagdanova; Patric S Lundberg; Dianne C Daniel
Journal:  Clin Dev Immunol       Date:  2013-04-15
View more
  7 in total

Review 1.  Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities.

Authors:  Alexios-Fotios A Mentis; Efthimios Dardiotis; Nikolaos Grigoriadis; Efthimia Petinaki; Georgios M Hadjigeorgiou
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

2.  Significance of Interviral Recombination as Novel Mechanism for Extending Viral Disease Repertoire.

Authors:  Edward M Johnson; Dianne C Daniel
Journal:  Brain Disord Ther       Date:  2016-06-23

3.  The Progressive Multifocal Leukoencephalopathy Consortium as a Model for Advancing Research and Dialogue on Rare Severe Adverse Drug Reactions.

Authors:  Ilse S Peterson; William O Iverson; Marion T Kasaian; Maggie Liu
Journal:  Adv Ther       Date:  2019-02-13       Impact factor: 3.845

Review 4.  Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.

Authors:  Allison Lm Jordan; Jennifer Yang; Caitlyn J Fisher; Michael K Racke; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2020-08-18       Impact factor: 6.312

5.  A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together.

Authors:  Eugene O Major; Avindra Nath
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-29

Review 6.  Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

7.  Identification of viral-mediated pathogenic mechanisms in neurodegenerative diseases using network-based approaches.

Authors:  Anna Onisiforou; George M Spyrou
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.